A 12-Week Treatment, Multi-Center, Randomized, Parallel Group, Blinded, Double Dummy Study to Compare the Efficacy and Safety of Indacaterol (150 microg o.d.) Delivered Via a SDDPI With Tiotropium (18 microg o.d.) Delivered Via a HandiHaler, in Patients With Moderate-to-Severe COPD.

Trial Profile

A 12-Week Treatment, Multi-Center, Randomized, Parallel Group, Blinded, Double Dummy Study to Compare the Efficacy and Safety of Indacaterol (150 microg o.d.) Delivered Via a SDDPI With Tiotropium (18 microg o.d.) Delivered Via a HandiHaler, in Patients With Moderate-to-Severe COPD.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 May 2016

At a glance

  • Drugs Indacaterol (Primary) ; Tiotropium bromide
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Acronyms INTENSITY
  • Sponsors Novartis
  • Most Recent Events

    • 02 May 2016 Study is single blind in Italy as per EudraCT record. Other countries from EudraCT record and NCT source is reporting it as double blind.
    • 24 Mar 2012 Planned number of patients changed from 1568 to 1600 as reported by European Clinical Trials Database record.
    • 01 Oct 2011 Results published in the European Respiratory Journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top